Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation

NCT00893399 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT00893399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00893399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Lead sponsor
University of Ulm
Phase
Phase 3
Overall status
Completed
Start date
May 12, 2010
Completion date
September 1, 2021
Enrollment
600 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia